The NAP SAPS
Prevalence of Nociplastic Pain Phenotype in Patients Diagnosed With Subacromial Pain Syndrome (SAPS) - a Cross-sectional Study
Sponsor study identifier
Secondary identifiers
OTHER_GRANT · The Region of Southern Denmark
OTHER_GRANT · Research Council of Lillebaelt Hospital
OTHER_GRANT · Research Council of Lillebaelt Hospital
observational
400
1 country
1
Study Start
October 19, 2026
Actual (reported)Primary Completion
August 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
August 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The goal of this cross-sectional study is to estimate the prevalence of the nociplastic pain phenotype, according to the IASP clinical criteria, among patients diagnosed with SubAcromial Pain Syndrome (SAPS). The main question it aims to answer is: What is the prevalence of the nociplastic pain phenotype in patients diagnosed with SAPS in an outpatient clinic? Primary outcome: Proportion of patients with SAPS meeting the IASP criteria for nociplastic pain.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
August 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 25, 2026
Actual (reported)August 28, 2026
Actual (reported)October 19, 2026
Actual (reported)August 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
August 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Proportion of patients with chronic Subacromial Pain Syndrome (SAPS) classified as having a nociplastic pain phenotype according to the IASP classification of nociplastic pain.
Grading system for nociplastic pain according to the International Association for the Study of Pain (IASP) classification of nociplastic pain (Kosek et al. 2021)
One time (baseline)
Difference in shoulder function between nociplastic and non-nociplastic pain phenotypes as assessed by the QuickDASH questionnaire
One time (baseline)
Difference in Kinesiophobia between nociplastic and non-nociplastic pain phenotypes as assessed by the Tampa Scale of Kinesiophobia (TSK) questionnaire.
Participants undergo a standardised clinical assessment including medical history, specific orthopedic shoulder test, diagnostic ultrasound and x-ray of the shoulder.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Patients referred to and evaluated at the specialised shoulder clinic at Vejle Hospital, Denmark
Vejle Hospital
Vejle, 7100, Denmark
Thomas Sørensen, PT, Cand.san
University of Southern Denmark
Kim G Ingwersen, Pt, PhD
University of Southern Denmark
Claus Varnum, Prof., PhD, MD
University of Southern Denmark
Henrik B Vægter, Prof., PT, PhD
Odense University Hospital and University of Southern Denmark
First Submitted
August 25, 2026
First Posted
August 28, 2026
Study Start
October 19, 2026
Actual (reported)Primary Completion
August 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
NUMITOR Study: Nummular Headache Iberian Study on the Treatments and Outcomes in Real-World Setting
one time (baseline)
Difference in Self-efficacy between nociplastic and non-nociplastic pain phenotypes according to the Pain Self-Efficacy Questionnaire (PSEQ4)
one time (baseline)
Difference in Overall health between nociplastic and non-nociplastic pain phenotype as assessed by the Health (WHO-5) questionnaire
One time (baseline)
Difference in Quality of life between nociplastic and non-nociplastic pain phenotype as assessed by the EQ-5D-5L questionnaire
One time (baseline)
Explorative outcome: Change in Movement-Evoked Pain during Virtual reality (VR) between nociplastic and non-nociplastic pain phenotype as measured by the Visual Analog Scale (VAS)
One time (baseline)
Explorative outcome: Change in degrees of shoulder movement during Virtual reality (VR) between nociplastic and non-nociplastic pain phenotype as measured by Range Of Movement (ROM) in degrees
One time (baseline)
Contact the study team to confirm eligibility.
Study Completion
August 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 23, 2026
Record last verified: 2026-10
Anonymised patient-level data for the primary objective and explorative outcome will be made available if required by the scientific journal, in which the results of the study are publiched.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: